– USA, MA – Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted and immuno-oncology therapies, today announced the appointment of Nadim Ahmed to its Board of Directors as President and CEO, effective immediately, succeeding Owen Hughes, who resigned.
“Nadim brings to Cullinan a proven track record in oncology drug development and commercialization success. His experience at Celgene during a period of tremendous growth will be invaluable to Cullinan as we advance Pearl into later-stage clinical development, while also moving our first two immuno-oncology programs, MICA and Florentine, into clinical trials by year-end 2021. We will provide an update for Pearl in Q4 2021 as originally planned. On behalf of Cullinan, I want to welcome Nadim to Cullinan and thank Owen for his contributions. We look forward to him supporting the transition.” commented Board Chairman, Anthony Rosenberg.
About Nadim Ahmed
Mr. Ahmed has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb, where he served as President, Hematology, and at Celgene Corporation where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Mr. Ahmed oversaw multiple product launches and participated as a member of the company’s Leadership Team. Before BMS, Mr. Ahmed served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst, Abraxane, and several key indications for Revlimid. Mr. Ahmed has worked with various treatment modalities, including small molecules, biologics, and cell therapy in hematology and solid tumors.
“I am excited to be leading the incredibly talented team at Cullinan to advance our deep, multi-modality pipeline as we strive to bring important medicines to cancer patients,” said Nadim Ahmed. “With a world-class leadership team in place and a robust cash position, Cullinan is well-poised to execute on its evolution into a company with multiple clinical-stage novel oncology programs.”
Mr. Ahmed holds a Master of Science degree from Loughborough University, UK, and a Bachelor of Science degree from University College London, UK.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company with a diversified pipeline of targeted and immuno-oncology therapeutic candidates across multiple modalities, with a focus on advanced-stage assets built on novel technology platforms with differentiated mechanisms, via both internal discovery and external collaboration.
For more information: https://www.cullinanoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
